- info@pro1laser.com
- 1-604-649-1234
- Monday 07.00 am - 12.00 pm Sunday
Menu
Background: Current treatment modalities are limited in their approach and success for hair loss. QR 678 & QR 678 Neo are new formulations, consisting of a combination of growth factors and peptides. This study demonstrates safety analysis of QR 678 & QR 678 Neo formulation, using in vitro cytotoxicity assay and in vivo animal efficacy.
Methods: Factors including vascular endothelial growth factor, basic fibroblast growth factor, insulin-like growth factor-1, keratinocyte growth factor, and copper tripeptide 1 (QR 678) or their biomimetic peptides (QR678 Neo) were suspended in a sterile injectable vehicle. The 3-2,5-diphenyl tetrazolium bromide assay was used to explore the cytotoxic effects of each factor used in the compositions in human keratinocyte cell and human fibroblast cell assays. An in vivo analysis, wherein study animals were given intradermal QR 678 & QR 678 Neo injections, was conducted to assess whether the formulations produce hair growth. Also, hair follicle viability was checked by intradermal injection of the pharmaceutical compositions in secondary alopecia.
Results: In both formulations, a positive response was observed with respect to the number of mice exhibiting hair growth at the injection sites. The injections caused retention of hair in a 0.25-cm radius around the injection site. On cytotoxicity study, all the factors were found to be safe in human keratinocyte cell and human fibroblast cell assay. A positive response was demonstrated in animals on treatment with the chemotherapeutic agent.
Conclusions: Intradermal injections of QR 678 & QR 678 Neo hair growth factor formulations are a safe and efficacious option for alopecia. Results seem encouraging enough to warrant a trial in humans with secondary alopecia, post cancer chemotherapy.
(Plast Reconstrue Surg Glob Open 2020;8:e2843; doi: 10.1097/GOX.0000000000002843; Published online 25 August 2020.)
QR678 & QR678 Neo Hair Growth Formulations: A Cellular Toxicity & Animal Efficacy Study Original article
The QR678® Neo therapy is a proprietary, first in class hair fall & hair regrowth therapy, which has revolutionized the treatment of hair fall in alopecia. This formulation was invented in India & has been named QR678 inspired by the new generation ubiquitous presence of “Quick Response“ QR code. 678 in Morse Code signifies “there is no answer”. This formulation has been named QR678® to signify a “Quick Response to a disease which earlier had no answer”.
The US and India patented QR678® Neo therapy is backed by 13+ clinical papers published in top international peer-reviewed journals. The biomimetic peptide formulation arrests hair fall & increases the thickness, number, and density of existing hair follicles leading to greater coverage in hair loss. The polypeptides used in the formulation mimic the action of specific human hair growth related growth factors that are naturally present in our scalp, making it natural growth factor-based treatment. The polypeptides penetrate deep into the scalp and provide nourishment to the scalp, which results in hair growth.
Exosomes are ‘signaling molecules’ that are injected into the scalp to trigger the secretion of growth factors. They are protein building blocks due to the presence of mRNA in their membrane. This mRNA synthesizes proteins according to its cell of origin. Therefore, when extracted from hair follicles, exosomes facilitate hair growth and can help prevent hair loss.
Although promising on paper, the research behind the rationale for exosome treatment is on-going. There is still a lot to learn about the efficacy and mechanism of action of exosome therapy. There is a need for reliable evidence in the form of research studies published in peer-reviewed journals with appropriate methodology to back the advent of exosome therapy for treatment of hair loss.
In the year 2019, the U.S. Food and Drug Administration issued a Public Safety Notification on exosome products stating the violative nature of “stem cells” products and their unsubstantiated claims in treating various conditions. The FDA clarified that currently there is no FDA-approved exosome product in the market.
The QR678® Neo therapy arrests hair fall & increases the thickness, number & density of existing hair follicles, leading to greater coverage in patients with alopecia. Since, the polypeptides used in QR678® Neo are anyways present in scalp full of hair (they get decreased in scalps which have hair fall), it is the enrichment of the scalp skin with these polypeptides which cause hair growth. Since these polypeptides are anyways normally present in the scalp, replenishing the scalp with these is not artificial and does not have any side effects
Unlike currently available hair fall treatments like minoxidil & finasteride, the QR678® Neo therapy is almost completely devoid of side effects. It is locally administered over the scalp skin by mesotherapy & as such is not absorbed into the systemic circulation. Unlike currently available hair transplant therapies like Follicular Unit Extraction (FUE) & Follicular Unit Transplantation (FUT), the QR678® Neo is non invasive, non surgical & therefore safer & more affordable. The QR678® Neo therapy works very well in androgenetic alopecia or male pattern baldness & female pattern hair loss. The QR678® Neo therapy has also demonstrated encouraging results in post chemotherapy induced hair loss, treatment of hair conditions like seborrheic dermatitis & in immunogenic diseases like alopecia areata.
QR678® Neo consists of a proprietary blend of natural growth factors, identical to those found in a healthy scalp, ensuring its safety for universal application. This precise formulation contains targeted concentrations of specific factors known to promote hair growth. With QR678® Neo, patients experience no side effects. The treatment is administered on an outpatient basis, with visible results emerging as early as eight weeks after commencement. Hear directly from our patients about their experiences with the QR678® Neo hair loss treatment.
QR678® Neo treatments involve 5 to 10 sessions, spaced approximately 2-3 weeks apart. Visible improvements can be observed within a few weeks following the commencement of the therapy. Once optimal results are attained, further injections are unnecessary unless hair loss recurs. This enduring effect is due to QR678® Neo’s capacity to rejuvenate hair follicles. Discover the reasons behind QR678® Neo’s high efficacy in reducing hair loss and enhancing hair regrowth.
QR678® Neo offers a safe treatment experience without any side effects, enabling you to continue with your day-to-day activities right after each session. It is recommended to use a mild shampoo at least a day post-treatment and refrain from scratching or rubbing the area treated. If any concerns arise, consult your treatment provider for guidance.
Genetic hair loss, often hereditary and observed in both men and women, can indeed be managed effectively if treatment commences early. This type of hair loss, which frequently runs in families, typically follows a distinctive pattern: an M or W shape in men and thinning along the hair part in women. If you have a family history of patterned baldness, it’s crucial to monitor your hair health closely and consult a doctor at the first sign of hair loss.
There are several well-established treatments for genetic hair loss, including:
Alopecia following chemotherapy is a widespread and emotionally impactful side effect of cancer treatments. The fear of hair loss often deters patients from undergoing necessary therapies. While hair loss from chemotherapy is usually temporary, regrowth can take months or even up to a year. However, recent advancements in treatment can expedite recovery:
These treatments offer hope and options for those facing hair loss due to chemotherapy, providing a path to recovery and helping to mitigate one of the most challenging aspects of cancer treatment.
QR678® Neo is a first-of-its-kind product developed by a group of clinical scientists after extensive research.
